Hyundai Bioscience Co. Ltd. · KRX:048410

Hyundai Bioscience Co. Ltd. financial statements

Hyundai Bioscience Co. Ltd.'s income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in KRW

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue3.52B15.1B9.48B7.85B9.24B12.5B30.1B31.2B32.0B36.1B
Cost of revenue3.27B3.18B4.44B5.17B5.72B5.95B16.0B16.9B17.1B24.1B
Gross profit243.6M11.9B5.04B2.68B3.52B6.56B14.1B14.3B14.8B12.0B
Research and development7.60B3.06B6.40B16.5B4.76B1.97B1.29B1.70B2.05B2.11B
Selling, general and administrative5.44B7.91B7.91B11.8B6.90B6.38B7.61B9.94B10.8B16.4B
Operating income-18.2B791.0M-14.6B-18.0B-17.3B-7.37B2.56B2.15B1.46B-6.96B
Depreciation and amortization1.31B633.8M1.11B1.29B1.48B3.78B3.81B1.82B1.71B982.8M
EBITDA-16.9B1.42B-13.4B-16.7B-15.8B-3.59B6.37B3.97B3.17B-5.98B
Interest expense2.43B2.31B314.6M448.7M3.00B1.13B0000
Income before tax-22.1B-6.93B-14.5B-16.6B-19.8B-8.38B1.29B3.26B1.21B-8.15B
Income tax326.5M178.8M150.2M-8.45M-79.3M
Net income-22.1B-6.93B-14.5B-15.8B-20.1B-8.61B767.2M2.62B1.22B-8.07B
Earnings per share, basic-230.41-87.01-364.25-398.36-518.69-239.6522.1577.6437.40-266.38

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents22.3B3.66B1.81B2.73B9.19B19.2B5.56B3.16B4.85B9.74B
Short-term investments17.7B10.0B16.0B13.0B1.50B2.66B3.00B
Receivables2.32B247.2M446.2M1.28B7.63B11.0B19.4B25.9B22.5B14.9B
Inventory1.14B1.08B2.59B2.95B3.35B4.21B6.08B4.18B5.88B6.66B
Current assets44.0B6.81B15.2B24.0B34.9B41.9B33.3B35.7B36.4B37.7B
Property, plant and equipment6.38B6.07B6.67B7.20B8.37B9.44B10.1B
Total assets130.7B67.7B52.8B67.3B80.5B92.3B63.2B54.0B49.5B53.4B
Accounts payable498.7M555.3M430.5M686.7M191.6M178.2M827.8M389.5M603.8M3.45B
Current liabilities19.5B27.5B6.95B8.38B16.7B9.58B14.5B11.4B18.5B27.9B
Long-term debt0111.1M29.1B1.00B1.50B7.01B
Total debt35.9B5.49B6.04B15.3B
Total liabilities20.0B28.3B7.52B9.09B19.0B41.1B16.2B13.5B18.6B35.2B
Shareholders' equity110.7B39.4B45.3B58.2B61.6B51.2B47.0B40.5B30.9B18.2B
Shares outstanding96.0M79.6M39.8M39.7M38.7M35.9M34.6M33.7M32.6M30.3M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-17.0B2.26B-6.01B-16.5B-538.5M7.50B9.18B5.01B-3.70B-4.34B
Capital spending-20.2B-2.17B-587.5M-1.54B-3.76B-25.2B-3.07B-7.07B-1.47B-6.98B
Free cash flow-37.2B87.5M-6.60B-18.1B-4.30B-17.7B-4.06B-2.06B-5.16B-11.3B
Cash from investing-19.7B5.18B8.52B-12.4B-26.8B-14.7B-4.63B654.9M-9.98B
Cash from financing19.2B-58.0M1.67B2.99B33.0B7.88B-2.10B-1.75B12.1B
Share buybacks140.0M1.09B3.60B4.45B2.11B
Change in cash18.7B1.84B-920.5M-6.46B-10.0B13.7B2.39B-1.69B-4.89B-2.17B